Bespoke Glycosylation Signatures

About Us

Thank you for visiting NeuImmune, an early-stage biopharmaceutical company in Maryland. Our focus is on developing innovative vaccines and biopharmaceuticals through the precision glycoengineering and delivery of biologics that address important medical and public health needs. We are committed to providing safe and more effective prophylactic and therapeutic treatments based on our novel biomanufacturing and delivery platforms in order to meet these needs.

Please find our corporate overview presentation below.

Please check the Power Point Presentation on the Overview Presentation Button

Overview Presentation

About Us

Learn about our team members and our vision.
Button
Our Science

Learn about the science and innovation behind our biopharmaceuticals.
Button
Pipeline

Learn about our pipeline and process.
Button
Learn more

Learn more about our research and our team by visiting the pages below.
Button

Slide title

Write your caption here

Button

Our mission

NeuImmune is a platform company that is developing a new generation of biopharmaceuticals using glycoengineered CHO cell lines for the precise production of prophylactic and therapeutic glycoproteins with significant global healthcare market and revenue impact. Sales of recombinant glycoproteins exceed 30 percent of the total biopharmaceutical market, and the precise manufacturing of biologically active and uniform glycoproteins can have extensive impacts on product efficacy, stability, and safety when used in vaccines and therapeutics.

Read More

Our proprietary technology is based on extensive computational models of CHO cell metabolism, protein secretion, and glycosylation that have allowed us to engineer complex traits into the cells over the past decade. This capability permits identification and production of optimal glycoforms in engineered CHO cell lines with predictable product profiles using our extensive panel of engineered cell lines and core competencies, including big data analytics and in silico modelling, intellectual property, and specialized know-how around cell line development.

We have also developed a complementary platform technology of polyphosphazene-based biopolymers that has been recognized for many years for its promise to provide an ideal combination of enhanced biocompatibility, stabilization, and safety profiles when used in combination with biopharmaceutical products. This includes our ability to develop specific custom-tailored polyphosphazenes with unique properties required for each targeted application, and to enable practical, reproducible, scalable manufacturing under stringent pharmaceutical conditions. Our advanced polyphosphazene platform, PPZ Technology, has significant potential to displace established alternatives in multi-billion dollar drug delivery and vaccine immunotherapeutic markets. We plan to pursue commercialization of the PPZ platform as a PPZ-based drug delivery system for precision engineered biopharmaceuticals, cancer immunotherapies, and improved immunoadjuvants for vaccines.

Biopharmaceutical solutions

In addition to our geCHO GlycoDesign technology, we have also developed a complementary platform technology of polyphosphazene-based biopolymers recognized for many years for its promise to provide an ideal combination of enhanced biocompatibility, stabilization, and safety profiles when used in combination with biopharmaceutical products. This includes our ability to develop specific custom-tailored polyphosphazenes with unique properties required for each targeted application and enable practical, reproducible, scalable manufacturing under stringent pharmaceutical conditions. Our advanced polyphosphazene platform, PPZ Technology, has significant potential to displace established alternatives in multi-billion dollar drug delivery and vaccine immunotherapeutic markets. NeuImmune plans to use the geCHO GlycoDesign technology and the PPZ technology for precision engineered biopharmaceuticals, cancer immunotherapies, and improved immunoadjuvants for vaccines.